Hives (Urticaria): Causes, Emergency Signs and 2026 Treatment Guidelines

Evidence reviewed: 8 November 2026. Urticaria (hives) causes suddenly appearing, often intensely itchy raised patches called wheals. Individual wheals usually disappear within 24 hours, though new ones can appear elsewhere. Some people also develop angioedema, a deeper swelling that may involve the lips, eyelids or other tissues. Most isolated hives are not life-threatening, but hives with difficulty breathing, throat swelling, faintness or other systemic symptoms may indicate anaphylaxis and require emergency treatment. Current treatment follows a stepwise approach based on the 2026 international urticaria guideline, beginning with modern second-generation antihistamines [1–3].

What causes hives?

Urticaria results from activation of skin mast cells, which release histamine and other mediators that increase blood-vessel permeability. Fluid enters the superficial skin, creating itchy, raised wheals. This process can be associated with infections, medications, specific physical triggers or immune dysregulation, but in many chronic cases there is no identifiable external allergen [1,2].

Hives may look red or pink in lighter skin, whereas they may appear skin-colored, purple, gray or dark brown in darker skin. The skin may be swollen even if redness is difficult to see [3].

Acute versus chronic urticaria: the correct definition

The 2026 international guideline defines acute urticaria as wheals, angioedema or both occurring for six weeks or less, and chronic urticaria as a recurring course for more than six weeks [1]. The original article incorrectly defined acute hives as lasting less than one week.

Type How it presents What it means
Acute urticaria Hives or angioedema for up to 6 weeks, often following an illness or other exposure. Usually resolves; evaluation focuses on history and emergency symptoms.
Chronic spontaneous urticaria (CSU) Recurring hives or angioedema for more than 6 weeks without a consistent external physical trigger. Often involves spontaneous mast-cell activation; a food allergy is rarely the explanation.
Chronic inducible urticaria (CIndU) Reproducible hives from a specific stimulus such as cold, pressure, heat, vibration, sunlight or scratching. Trigger and threshold assessment can help guide avoidance and treatment.

A person can have more than one subtype. Some patients with CSU report worsening from heat, stress or pressure even though these are not the sole cause of their illness [1].

What does an individual wheal look like?

An ordinary hive is a transient, raised, itchy or sometimes burning patch that generally vanishes within 30 minutes to 24 hours, leaving skin without permanent bruising or scarring. New wheals may arise in other places, making the overall rash seem constant [1].

A lesion that remains fixed for more than 24 hours, is predominantly painful rather than itchy, or leaves bruising/purpura should prompt evaluation for alternatives such as urticarial vasculitis. Other mimics include eczema, insect bites, erythema multiforme and certain autoinflammatory conditions. Photos can be useful if lesions disappear before a visit, but they do not establish the cause.

Angioedema and anaphylaxis: know the difference

Angioedema is deeper swelling, frequently affecting lips, eyelids, hands or genital tissue. It can occur with hives or separately. Anaphylaxis is a serious systemic reaction that may involve airway swelling, breathing difficulty, low blood pressure, fainting, gastrointestinal symptoms or rapidly progressing illness [1,3].

Call emergency services immediately for difficulty breathing, wheezing, throat or tongue swelling, trouble swallowing, hoarse voice, collapse or faintness, particularly after an allergen exposure. If an epinephrine (adrenaline) auto-injector has been prescribed for anaphylaxis, use it promptly according to the person’s emergency plan while arranging emergency services. Antihistamines do not replace epinephrine for anaphylaxis.

Angioedema without wheals may sometimes result from a different pathway, such as a bradykinin-mediated reaction to an ACE inhibitor or hereditary angioedema. These forms may not respond well to usual antihistamines and require targeted assessment. Any tongue or throat swelling remains an emergency regardless of the suspected mechanism [1].

Common triggers and aggravating factors

  • Viral and other infections: a common association with acute urticaria, especially in children.
  • Drugs: certain antibiotics, NSAIDs and other medicines can provoke hives in susceptible people.
  • True allergy: foods, medicines or insect stings can cause rapid-onset hives, sometimes with anaphylaxis; confirm with an appropriate history and targeted testing.
  • Physical stimuli: cold exposure, scratching, pressure, heat, sweating or sunlight in chronic inducible forms.
  • Exacerbating factors: stress, alcohol or NSAIDs may worsen chronic disease in some individuals, but do not necessarily explain its underlying cause.

Do not assume that chronic spontaneous urticaria means a hidden food allergy. Indiscriminate food elimination, repeated allergy panels and unsupported “histamine detoxes” can create anxiety and nutritional harm without controlling disease [1,2].

How is urticaria diagnosed?

Diagnosis usually starts with history and clinical examination: onset, length of each individual lesion, recurrence, associated swelling, medicines (especially NSAIDs and ACE inhibitors), infection symptoms and obvious inducible triggers. For acute uncomplicated urticaria, broad allergy and blood-test panels are usually unnecessary unless the history suggests a specific cause [1,3].

For chronic spontaneous urticaria, the 2026 guideline recommends a limited baseline investigation, often including a blood count with differential and CRP and/or ESR, with other testing driven by the history and specialist assessment. Total IgE and anti-thyroid peroxidase antibodies may be useful in specialized care for treatment context or endotyping; they are not universal diagnostic requirements. For inducible disease, controlled provocation and trigger-threshold testing may be appropriate [1].

First-line treatment: second-generation H1 antihistamines

The 2026 international guideline strongly recommends a modern second-generation H1 antihistamine as first-line symptomatic treatment for urticaria. Examples include cetirizine, fexofenadine, loratadine, desloratadine, levocetirizine, bilastine and rupatadine, subject to local approvals and patient factors [1].

These medicines block H1 histamine receptors and help reduce itching and new wheal formation. They generally have fewer sedation and anticholinergic problems than older agents, but some can still cause drowsiness in certain people. First-generation sedating antihistamines such as diphenhydramine are not recommended as routine first-line chronic therapy because of adverse effects, impaired performance and overdose concerns [1].

For chronic spontaneous urticaria, regular daily treatment is usually preferable to taking medicine only after severe itching develops. Individual drug selection depends on age, kidney or liver function, interactions and local product guidance [1].

If one standard dose does not work

The guideline recommends that, for chronic urticaria inadequately controlled by a standard-dose second-generation antihistamine, clinicians consider increasing the dose of a single suitable second-generation antihistamine up to fourfold before moving to advanced therapies [1].

This up-dosing is often off-label, should be supervised by an appropriate clinician, and must account for the specific drug and patient. The recommendation does not mean every person should take four tablets of any antihistamine; nor does it support exceeding fourfold dosing or combining multiple different H1 medicines indiscriminately. Extra caution is needed for children, pregnancy and patients with organ impairment [1].

Specialist treatments for persistent chronic spontaneous urticaria

For patients whose chronic hives remain uncontrolled despite appropriate antihistamine treatment, the 2026 international guideline and US guidance recognize several advanced add-on options. Their comparative effectiveness, safety, access and licensing vary [1,4].

Therapy Mechanism and role Important cautions
Omalizumab Anti-IgE monoclonal antibody; a well-established add-on treatment for antihistamine-refractory CSU. Injected on a defined schedule; monitor clinical response and injection-related or other adverse reactions.
Dupilumab Blocks IL-4/IL-13 signaling through IL-4 receptor alpha; approved for eligible CSU patients in several settings. Injection therapy; eye effects, injection reactions, indication and age-specific licensing require review.
Remibrutinib Oral Bruton’s tyrosine kinase (BTK) inhibitor that modulates mast-cell signaling; FDA-approved for adult CSU refractory to antihistamines since 2025. Review bleeding risk, potential interactions, medical history and current prescribing information.
Ciclosporin Immunosuppressant sometimes used for severe refractory disease when licensed treatments fail or are unavailable. Generally off-label; kidney function, blood pressure, interactions and infection risks require specialist monitoring.

The updated international guideline strongly supports adding omalizumab for suitable patients inadequately controlled on high-dose antihistamines and suggests dupilumab or remibrutinib in selected cases. Ciclosporin is reserved for difficult disease because of its adverse-effect burden. These are not medications for self-prescribing, and no one treatment is guaranteed to cure every type of hives [1,4,5].

The US FDA approved remibrutinib in September 2025 for eligible adults with CSU inadequately controlled by H1-antihistamines, and dupilumab has an approved CSU indication with age eligibility specified in current labels. Licensing, age thresholds and coverage may differ by country and change over time; follow the latest local product information [5].

Why long-term corticosteroids are not recommended

Systemic corticosteroids such as prednisone can suppress inflammation rapidly, but prolonged use is strongly discouraged for chronic urticaria under the 2026 guideline because of infections, hypertension, diabetes, bone loss, adrenal suppression and other risks. A very short rescue course may occasionally be considered by a clinician for an acute severe exacerbation, but is not a maintenance strategy [1].

Topical corticosteroids do not reliably control the underlying mast-cell-driven process in recurrent hives and are not a substitute for appropriate systemic antihistamines. Cooling lotions and gentle moisturizers may provide comfort, but they do not prevent new wheals.

What can help at home?

  • Use cool compresses and avoid hot showers if heat worsens itching.
  • Wear loose, breathable clothing and reduce avoidable pressure or friction when relevant.
  • Keep a symptom diary, noting the duration of individual lesions, any angioedema, medicines and reproducible physical triggers.
  • Discuss NSAID-related worsening with a clinician rather than abruptly stopping necessary prescriptions.
  • For cold-induced urticaria, avoid dangerous cold-water immersion if reactions are severe or systemic and seek specialist assessment.
  • Consider the impact on sleep, work and mental health; treatment should address quality of life as well as visible lesions.

Home remedies cannot replace emergency care or advanced treatment when symptoms are severe. Routine elimination diets, antibiotics or antifungals are not indicated without another established diagnosis.

How is disease control measured?

Clinicians may use the Urticaria Activity Score over seven days (UAS7), which summarizes wheals and itch, and the Urticaria Control Test (UCT) to assess ongoing control. For angioedema, additional validated patient-reported measures are available. These tools guide follow-up and treatment adjustment, but they are not stand-alone diagnostic tests [1].

Hives during pregnancy or childhood

Pregnancy and childhood require specific medicine selection. A clinician may recommend a suitable second-generation antihistamine after considering safety, symptoms and age. Do not independently use off-label fourfold doses during pregnancy or give adult dosing to children. The availability of advanced treatment in children depends on exact product licensing and specialist assessment. Severe airway symptoms in pregnancy or a child remain an emergency.

Frequently asked questions

Is every hive rash caused by food allergy?

No. Many acute episodes follow infections, and chronic spontaneous urticaria often has no consistent external allergen [1].

Does each hive need to last six weeks to be chronic?

No. Individual wheals usually resolve in 24 hours; chronic urticaria means the overall recurring illness lasts more than six weeks.

Can antihistamines be increased to four times a usual dose?

The 2026 guideline supports selected second-generation antihistamine up-dosing under clinician supervision, often off-label; never self-escalate indiscriminately [1].

Should I take prednisone for months for hives?

No. Long-term systemic corticosteroids are strongly discouraged for chronic urticaria [1].

When should I call emergency services?

Immediately for throat or tongue swelling, breathing difficulty, fainting or suspected anaphylaxis. Antihistamines alone are not emergency treatment for anaphylaxis.

Key takeaways

Most hives are transient, but recurrent disease may require a structured treatment plan. The 2026 guideline recommends second-generation H1 antihistamines first, supervised up-dosing when appropriate, and advanced therapies such as omalizumab, dupilumab or remibrutinib in selected refractory cases. Never confuse hives with anaphylaxis when breathing or circulation is affected.

References

  1. Zuberbier T, et al. The international guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2026. doi:10.1111/all.70210.
  2. British Society for Allergy and Clinical Immunology. International urticaria guideline published: 2026 update.
  3. American Academy of Dermatology. Hives: diagnosis and treatment. Accessed 8 Nov 2026.
  4. American College of Allergy, Asthma and Immunology. 2026 AAAAI/ACAAI Joint Task Force chronic urticaria guideline and supporting materials.
  5. US Food and Drug Administration. Drug trials snapshot: Rhapsido (remibrutinib). Original approval 30 Sep 2025.

Medical disclaimer: This article is general information and not a prescription. Do not exceed labeled antihistamine doses without clinician supervision or stop prescribed medicines independently. Throat swelling, breathing problems, collapse or suspected anaphylaxis are emergencies—call local emergency services immediately.

Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *